Using Calcitonin Gene-related Peptide Monoclonal Antibodies for Migraine Headache Treatment and Prevention

Main Article Content

Nour Al-Kharrat
Gunay Arsoy

Abstract

Novel drugs are available now for treating and preventing migraine attacks. Those new drugs have a special strategy to treat migraine by modifying the signaling of calcitonin gene- related peptide (CGRP) which is a strong neuropeptide released from the nerves. Monoclonal antibodies (mAbs) have been developed for targeting the CGRP pathway by binding the CGRP ligand (eptinezumab, galcanezumab fremanezumab,) or the CGRP receptor (erenumab). Recent studies show that mAbs have several advantages over small molecule antagonists, including high selectivity and reduced potential for drug–drug interactions. In this article we reviewed literature to assess whether mABs can be used for treatment of acute and chronic migraine safely compared to classical antimigraine agents.

Keywords:
Migraine, CGRP, monoclonal antibodies, treatment, prevention.

Article Details

How to Cite
Al-Kharrat, N., & Arsoy, G. (2019). Using Calcitonin Gene-related Peptide Monoclonal Antibodies for Migraine Headache Treatment and Prevention. Asian Journal of Research and Reports in Neurology, 2(2), 1-8. Retrieved from http://journalajorrin.com/index.php/AJORRIN/article/view/30100
Section
Review Article

References

GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–1602.

Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinica features, and pathophysiology of migraine. Lancet Neurol. 2017;16:76–87.

Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629–808.

Burstein B, Noseda R, Borsook D. Migraine: Multiple processes, complex pathophysiology. J Neurosci. 2015;35: 6619–6629.

Akerman S, Romero-Reyes M, Holland PR. Current and novel insights into theneurophysiology of migraine and its implications for therapeutics. Pharmacol Thr; 2016.

Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337–1345.

Gracia-Naya M, Santos-Lasaosa S, Rı´os-Go´mez C, Sánchez-Valiente S, García-Gomara MJ, Latorre-Jiménez AM, Artal-Roy J, Mauri-Llerda JA. Predisposing factors affecting drop-out rates in preventive treatment in a series of patients with migraine. Rev Neurol. 2011;53:201–208.

Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35:478–488.

Edvinsson L, Warfvinge K. Recognizing the role of CGRP and CGRP receptors in migraine and its treatment. Cephalalgia. 2019;39(3):366-373.

Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia. 2002;22(1):54-61.

Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine like attacks in patients with migraine with aura. Cephalalgia. 2010;30(10):1179-1186.

Cernuda-Morollon E, Larrosa D, Ramon C, Vega J, Martinez-Camblor P, Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013;81(14):1191-1196.

Warfvinge K, Edvinsson L. Distribution of CGRP and CGRP receptor components in the rat brain. Cephalalgia. 2019;39(3):342-353.

Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94(4):1099–1142.

MaassenVanDenBrink A, Meijer J, Villalon CM, Ferrari MD. Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci. 2016;37(9):779–788.

Goadsby PJ, Edvinsson L. Joint 1994 Wolff award presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache. 1994;34(7):394-399.

Edvinsson L, Goadsby PJ. Neuropeptides in migraine and cluster headache. Cephalalgia. 1994;14(5):320-7.

Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol. 1993;33(1):48-56.

Goadsby, PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain. 1994;117(3):427-34.

Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br. J. Clin. Pharmacol. 2015;80(2):193-9.

Bell IM. Calcitonin gene- related peptide receptor antagonists: new therapeutic agents for migraine. J. Med. Chem. 2014;57(19):7838-58.

Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double- blind, placebo- controlled phase 2 trial. Lancet Neurol. 2017;16(6):425-434.

Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J, Lenz R. Safety and efficacy of AMG 334 for prevention of episodic migraine: A randomised, double- blind, placebo- controlled, phase 2 trial. Lancet Neurol. 2016;15(4):382-90.

Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J, ALD403 study investigators.Safety and efficacy of ALD403, an antibody to calcitonin gene- related peptide, for the prevention of frequent episodic migraine: a randomised, double- blind, placebo controlled, exploratory phase 2 trial. Lancet Neurol. 2014;13(11):1100-1107.

Bigal ME, Dodick DW, Krymchantowski AV, VanderPluym JH, Tepper SJ, Aycardi E, Loupe PS, Ma Y, Goadsby PJ. TEV-48125 for the preventive treatment of chronic migraine: efficacy at early time points. Neurology. 2016;5;87(1):41-8.